GlycoEpitope: show

Sialyl Lewis a

Epitope information of EP0008

Epitope ID	EP0008
Epitope name	Sialyl Lewis a
Structure
Sequence	Neu5Ac(a2-3)Gal(b1-3)[Fuc(a1-4)]GlcNAc(b1-)-R
Aliases	Sialyl Le^a ,carbohydrate antigen 19-9 / CA19-9
History	Sialyl Le^a was characherized as a tumor marker.[9 *] The term Lewis refers to the family name of individuals suffering from a red blood cell incompatibility problem that helped lead to the discovery of this blood group.
DB	GlyTouCan:G00053MO JCGGDB
Molecular weight	820.8
Composition	(Gal)1(GlcNAc)1(Fuc)1(Neu5Ac)1
Species	Homo sapiens
Tissue and Cellular distribution
Subcellular distribution
Developmental change	In normal tissues,Sialyl Le^a antigen is expressed in biliary and pancreatic duct epithelia.[4] Sialyl Le^a is expressed in many malignant cells.[5]
Cell line	B16/mouse melanoma BxPC-3/human pancreatic carcinoma COLO 205/human colon adenocarcinoma HL-60/human promyelocytic leukemia HT-29/human colon adenocarcinoma HT-29LMM/metastatic parental
Receptor	E-selectin P-selectin[10][11 *]
Function	The carbohydrate determinants,Sialyl Le^a and Sialyl Le^x,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[3]
Diseases	pancreatic adenocarcinoma hepatocellular cancer cholangiocellular cancer gastric cancer colorectal cancer[24] ovarian cancer lung cancer breast cancer uterine cancer CA 19-9 is detected with highest levels in excretory ductal pancreatic adenocarcinoma, biliary, hepatocellular and cholangiocellular cancer besides gastric, colorectal and ovarian cancer and occasionally in lung, breast and uterine cancer.[2]
Application	The monoclonal antibody NS 19-9 is a representative diagnostic agent for pancreatic adenocarcinoma and cholangiocellular cancer.
Comment	Mucins and BGM (bile globular membrane)(see Reference) are CA19-9 carriers in sera of patients with cancer.[25]

Epitope ID

EP0008

Epitope name

Sialyl Lewis a

Structure

Sequence

Neu5Ac(a2-3)Gal(b1-3)[Fuc(a1-4)]GlcNAc(b1-)-R

Aliases

Sialyl Le^a ,carbohydrate antigen 19-9 / CA19-9

History

Sialyl Le^a was characherized as a tumor marker.[9 *]
The term Lewis refers to the family name of individuals suffering from a red blood cell incompatibility problem that helped lead to the discovery of this blood group.

GlyTouCan:G00053MO JCGGDB

Molecular weight

820.8

Composition

(Gal)1(GlcNAc)1(Fuc)1(Neu5Ac)1

Species

Homo sapiens

Tissue and Cellular distribution

Subcellular distribution

Developmental change

In normal tissues,Sialyl Le^a antigen is expressed in biliary and pancreatic duct epithelia.[4]
Sialyl Le^a is expressed in many malignant cells.[5]

Cell line

B16/mouse melanoma
BxPC-3/human pancreatic carcinoma
COLO 205/human colon adenocarcinoma
HL-60/human promyelocytic leukemia
HT-29/human colon adenocarcinoma
HT-29LMM/metastatic parental

Receptor

E-selectin
P-selectin[10][11 *]

Function

The carbohydrate determinants,Sialyl Le^a and Sialyl Le^x,which are frequently expressed on human cancer cells,serve as ligands for a cell adhesion molecule of the selectin family,E-selectin,which is expressed on vascular endothelial cells. These carbohydrate determinants are involved in the adhesion of cancer cells to vascular endothelium and thus contribute to hematogenous metastasis of cancer.[3]

Diseases

pancreatic adenocarcinoma
hepatocellular cancer
cholangiocellular cancer
gastric cancer
colorectal cancer[24]
ovarian cancer
lung cancer
breast cancer
uterine cancer

CA 19-9 is detected with highest levels in excretory ductal pancreatic adenocarcinoma, biliary, hepatocellular and cholangiocellular cancer besides gastric, colorectal and ovarian cancer and occasionally in lung, breast and uterine cancer.[2]

Application

The monoclonal antibody NS 19-9 is a representative diagnostic agent for pancreatic adenocarcinoma and cholangiocellular cancer.

Comment

Mucins and BGM (bile globular membrane)(see Reference) are CA19-9 carriers in sera of patients with cancer.[25]